% | $
Quotes you view appear here for quick access.

Sanofi Message Board

  • carl463681 carl463681 Aug 29, 2010 9:50 AM Flag

    O.T. "XOMAD" Potential Takeover Target By SNY or GSK


    XOMA's 052 Designated Orphan Drug by FDA

    Xoma Presenting at the Rodman & Renshaw Annual Global Investment Conference 12th Annual Healthcare Conference September 12-15, 2010 New York, NY

    Listen to XOMA Ltd. Second Quarter 2010 Financial Results Conference Call (8/9/2010) for an overview of the situation:

    "XOMAD should be above $6.00 here."

    "Last week's 1 – 15 reverse split is impacting the share price."

    "Substantially oversold."

    "Current price is equal to about 18 cents pre-split."

    "52 week high was $16.05 on a post split basis. Bottomed at $2.45 on Tuesday."

    "Current market cap is only $64 million. Companies with no track record of product development and a similar drug in the pipeline are valued at many times what XOMA is currently."

    "GSK needs a replacement for Avandia. Potential suitor."

    "SNY has spent over $17 billion on 25 acquisitions over the last two years."

    "Company is currently self-funded through the next 12 months with almost $100,000,000 in revenues."

    "Buy it before the gap-up."

    "Partnership announcement takes it above $20.00."

    "Due diligence but do buy a few shares here."

    This topic is deleted.
    SortNewest  |  Oldest  |  Most Replied Expand all replies
38.98+0.61(+1.59%)Feb 12 4:01 PMEST